Experimental Autism Drug Will Enter Phase Three Trials
The drug L1-79 targets core social interaction difficulties in autism as researchers plan new trials for 2027.
Updated on Oct. 1, 2026 in Autism
Yamo Pharmaceuticals is preparing to advance its experimental autism drug L1-79 to phase three clinical trials by 2027. The drug, which is not yet approved by the FDA, aims to address core social interaction symptoms rather than associated conditions.
Why it matters
Current FDA-approved medications for autism are limited to treating associated symptoms, meaning there remains a significant gap in care for addressing core social interaction difficulties. This development reflects an ongoing effort to identify targeted pharmacological options for this specific clinical need.
A 2019 case series followed eight participants for eight weeks, noting behavioral improvements in seven of them, followed by a larger phase two trial of 58 adolescents and young adults. As these findings are preliminary, the drug remains under investigation in clinical settings.
The players
Yamo Pharmaceuticals
A pharmaceutical developer focused on creating treatments for core symptoms of autism spectrum disorders.
Matthew Bielski
An investor in Yamo Pharmaceuticals who launched the Autism Impact ETF to support autism-related causes.
The details
L1-79 is administered as a twice-daily oral treatment designed to influence social interaction symptoms in individuals with autism. While currently lacking formal approval, the drug has been granted Fast Track designation by the FDA and is available to some through the agency's expanded-access program. Further clinical validation is required to confirm how the treatment interacts with neurological pathways to improve social behaviors.
Timeline
A case series detailing initial outcomes was published in 2019.
Yamo Pharmaceuticals plans to move toward phase three trials in 2027.
Health Landscape
The development of L1-79 aligns with the FDA's Fast Track designation, a program intended to accelerate the evaluation of treatments for serious unmet medical needs. This trajectory marks a departure from existing autism management, which currently relies on therapies focused on associated symptoms.
Families seeking experimental options for social interaction difficulties may explore the FDA's expanded-access program for information on current availability. These potential treatments should always be discussed with a clinician to understand the risks and clinical status.
The takeaway
While L1-79 aims to address core social interaction difficulties in autism, it remains in the clinical trial pipeline and lacks full FDA approval. Patients and families are encouraged to monitor future phase three trial outcomes as they emerge in 2027.
Further reading
For more background on the evolving research landscape for this condition, visit Autism.
Source note: This article includes information reported by Dailywire.
